"Our previous research has shown that this narrowing of blood vessels contributes significantly to 'no-reflow,' a complication that increases the risk of death or hospital admission for heart failure within a year of a heart attack
Steuerman et al conducted a large worldwide survey on the prevalence of cancer in patients with various causes of secondary congenital IGF-1 deficiency and confirmed that subjects with Laron syndrome with congenital IGF-1 deficiency seem protected from the development of cancer [2]
CCLE transcriptomics, and metabolomics data were used in building our models [34, 42]
News Article How Asian pharma suppliers cash in on Ozempic copies Oct 31, 2024 By Andrew Silver SHANGHAI (Reuters) - Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro and Orsema, developed by a little-known Bangladeshi drugmaker, Incepta Pharmaceuticals
The truth: Taking action = results
